Idioma:

Acute myeloid leukaemia

Short, Nicholas J ; Rytting, Michael E ; Cortes, Jorge E

The Lancet (British edition), 2018-08, Vol.392 (10147), p.593-606 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por

Enviar para

Título:
Acute myeloid leukaemia
Autor: Short, Nicholas J ; Rytting, Michael E ; Cortes, Jorge E
Assuntos: Acute myeloid leukemia ; Age ; Aminoglycosides - therapeutic use ; Antibodies, Monoclonal, Humanized - therapeutic use ; Antineoplastic Agents - therapeutic use ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Bone marrow ; Chemotherapy ; Clinical trials ; Cloning ; Consolidation Chemotherapy ; Cytarabine - administration & dosage ; Cytotoxicity ; Drug development ; Drug dosages ; Drugs ; FDA approval ; Gemtuzumab ; Genomes ; Genomics ; Health risks ; Hematology ; Hematopoietic Stem Cell Transplantation ; Humans ; Leukemia ; Leukemia, Myeloid, Acute - diagnosis ; Leukemia, Myeloid, Acute - drug therapy ; Leukemia, Myeloid, Acute - genetics ; Leukemia, Myeloid, Acute - therapy ; Medical prognosis ; Medical research ; Mutation ; Older people ; Pathogenesis ; Patient Selection ; Patients ; Recurrence ; Regulatory approval ; Remission Induction ; Response rates ; Risk Assessment ; Risk Factors ; Risk management ; Staurosporine - analogs & derivatives ; Staurosporine - therapeutic use ; Stem cells ; Tumors
É parte de: The Lancet (British edition), 2018-08, Vol.392 (10147), p.593-606
Notas: All authors participated in the development and review of the manuscript and gave approval of the final version.
Contributors
Descrição: For several decades, few substantial therapeutic advances have been made for patients with acute myeloid leukaemia. However, since 2017 unprecedented growth has been seen in the number of drugs available for the treatment of acute myeloid leukaemia, with several new drugs receiving regulatory approval. In addition to advancing our therapeutic armamentarium, an increased understanding of the biology and genomic architecture of acute myeloid leukaemia has led to refined risk assessment of this disease, with consensus risk stratification guidelines now incorporating a growing number of recurrent molecular aberrations that aid in the selection of risk-adapted management strategies. Despite this promising recent progress, the outcomes of patients with acute myeloid leukaemia remain unsatisfactory, with more than half of patients ultimately dying from their disease. Enrolment of patients into clinical trials that evaluate novel drugs and rational combination therapies is imperative to continuing this progress and further improving the outcomes of patients with acute myeloid leukaemia.
Editor: England: Elsevier Ltd
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Resultado 1 Avançar Ir para próxima página

Realização: Logos de Redes Sociais:

Acute myeloid leukaemia

Short, Nicholas J ; Rytting, Michael E ; Cortes, Jorge E

England: Elsevier Ltd

Buscando em bases de dados remotas. Favor aguardar.